PODD Quote, Financials, Valuation and Earnings

iRhythm Technologies has a net margin of 6.22% compared to Insulet's net margin of -19.35%. Insulet's return on equity of 36.9% beat iRhythm Technologies's return on equity of -112.03%.

Insulet has a consensus price target of $334.74, signalling upside risk potential of 7.37%. On the other hand iRhythm Technologies has an analysts' consensus of $141.33 which suggests that it could fall by -3.65%. Given that Insulet has higher upside potential than iRhythm Technologies, analysts believe Insulet is more attractive than iRhythm Technologies.

Insulet has a beta of 1.375, which suggesting that the stock is 37.475% more volatile than S&P 500. In comparison iRhythm Technologies has a beta of 1.402, suggesting its more volatile than the S&P 500 by 40.168%.

Insulet has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iRhythm Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insulet pays -- of its earnings as a dividend. iRhythm Technologies pays out -- of its earnings as a dividend.

Insulet quarterly revenues are $569M, which are larger than iRhythm Technologies quarterly revenues of $158.7M. Insulet's net income of $35.4M is higher than iRhythm Technologies's net income of -$30.7M. Notably, Insulet's price-to-earnings ratio is 56.07x while iRhythm Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet is 10.49x versus 7.43x for iRhythm Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical has a net margin of 6.22% compared to Insulet's net margin of 30.99%. Insulet's return on equity of 36.9% beat Intuitive Surgical's return on equity of 15.82%.

Insulet has a consensus price target of $334.74, signalling upside risk potential of 7.37%. On the other hand Intuitive Surgical has an analysts' consensus of $578.17 which suggests that it could grow by 3.79%. Given that Insulet has higher upside potential than Intuitive Surgical, analysts believe Insulet is more attractive than Intuitive Surgical.

Insulet has a beta of 1.375, which suggesting that the stock is 37.475% more volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.669, suggesting its more volatile than the S&P 500 by 66.875%.

Insulet has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insulet pays -- of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend.

Insulet quarterly revenues are $569M, which are smaller than Intuitive Surgical quarterly revenues of $2.3B. Insulet's net income of $35.4M is lower than Intuitive Surgical's net income of $698.4M. Notably, Insulet's price-to-earnings ratio is 56.07x while Intuitive Surgical's PE ratio is 81.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet is 10.49x versus 23.21x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

Masimo has a net margin of 6.22% compared to Insulet's net margin of -45.89%. Insulet's return on equity of 36.9% beat Masimo's return on equity of -39.91%.

Insulet has a consensus price target of $334.74, signalling upside risk potential of 7.37%. On the other hand Masimo has an analysts' consensus of $182.07 which suggests that it could grow by 5.88%. Given that Insulet has higher upside potential than Masimo, analysts believe Insulet is more attractive than Masimo.

Insulet has a beta of 1.375, which suggesting that the stock is 37.475% more volatile than S&P 500. In comparison Masimo has a beta of 1.187, suggesting its more volatile than the S&P 500 by 18.725%.

Insulet has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insulet pays -- of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend.

Insulet quarterly revenues are $569M, which are larger than Masimo quarterly revenues of $372M. Insulet's net income of $35.4M is higher than Masimo's net income of -$170.7M. Notably, Insulet's price-to-earnings ratio is 56.07x while Masimo's PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet is 10.49x versus 4.73x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of 6.22% compared to Insulet's net margin of 28.26%. Insulet's return on equity of 36.9% beat ResMed's return on equity of 25.76%.

Insulet has a consensus price target of $334.74, signalling upside risk potential of 7.37%. On the other hand ResMed has an analysts' consensus of $264.49 which suggests that it could grow by 4.87%. Given that Insulet has higher upside potential than ResMed, analysts believe Insulet is more attractive than ResMed.

Insulet has a beta of 1.375, which suggesting that the stock is 37.475% more volatile than S&P 500. In comparison ResMed has a beta of 0.778, suggesting its less volatile than the S&P 500 by 22.169%.

Insulet has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.84% to investors and pays a quarterly dividend of $0.53 per share. Insulet pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Insulet quarterly revenues are $569M, which are smaller than ResMed quarterly revenues of $1.3B. Insulet's net income of $35.4M is lower than ResMed's net income of $365M. Notably, Insulet's price-to-earnings ratio is 56.07x while ResMed's PE ratio is 28.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet is 10.49x versus 7.41x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.